Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02236559 · ClinicalTrials.gov registry record · NA
High Flow Therapy for the Treatment of Respiratory Failure in the ED
A NA study of Acute Respiratory Failure, sponsored by Vapotherm.
- Completed
- Registry status
- NA
- Development phase
- 204
- Enrollment target
- 5
- Study locations
NCT02236559 is a NA study of Acute Respiratory Failure that has completed, run by Vapotherm. The registered enrollment target is 204 participants, below the 1,466-participant average among 13 other Acute Respiratory Failure trials with a reported enrollment target (86% lower). The trial reports 5 study locations across 4 states.
The verdict
NCT02236559, a NA study of Acute Respiratory Failure, has completed, sponsored by Vapotherm.
- COMPLETED
- Registry status
- NA
- Development phase
- 204 participants
- Enrollment target
- 5
- Study locations
Study Summary
The overall objective of this study is to determine if Vapotherm high flow nasal cannula therapy (HFT), when used to treat respiratory failure in the ED, is at least equivalent to the current standard of care for non-invasive ventilatory support, non-invasive positive pressure mask ventilation (NIPPV). Moreover, this study will investigate the potential that HFT has possible advantages over NIPPV, such as decreased time to patient stability from respiratory failure, and the ease of use as a first line intervention for respiratory failure in the ED environment. The hypothesis is that HFT via the Vapotherm Precision Flow will demonstrate clinical non-inferiority when compared to NIPPV with regard to treatment failure by way of an impact on ventilation indices and a lower intolerance rate, and have a positive association with hospital disposition and length of stay.
Conditions Studied
Interventions
- DEVICE Vapotherm
- DEVICE Noninvasive positive pressure ventilation (NIPPV)
Study Locations (5)
Texas
- Memorial Hermann Hospital - Houston
- Memorial Hermann The Woodlands - The Woodlands
Georgia
- Athens Regional Medical Center - Athens
South Carolina
- McLeod Regional Medical Center - Florence
Tennessee
- Erlanger Health System - Chattanooga
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 204 participants |
| Start Date | 2014-09 |
| Est. Completion | 2017-02 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02236559
The ClinicalTrials.gov registry entry for NCT02236559 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 204 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,466-participant average among 13 other Acute Respiratory Failure trials with a reported enrollment target (86% lower). The listed sponsor is Vapotherm, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acute Respiratory Failure appearing as the primary indexed condition, and to 2 interventions - of which Vapotherm is the first listed.
NCT02236559 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Texas, Georgia, South Carolina.
Frequently Asked Questions
What is clinical trial NCT02236559 about?
NCT02236559 is a clinical study titled "High Flow Therapy for the Treatment of Respiratory Failure in the ED". The overall objective of this study is to determine if Vapotherm high flow nasal cannula therapy (HFT), when used to treat respiratory failure in the ED, is at least equivalent to the current standard of care for non-invasive ventilatory support, non-invasive positive pressure mask ventilation (NIPP...
What is the current status of trial NCT02236559?
This trial is currently completed. It is a NA study. The enrollment target is 204 participants. The study started on 2014-09. Estimated completion is 2017-02.
What conditions does trial NCT02236559 study?
This clinical trial studies the following conditions: Acute Respiratory Failure.
What interventions are being tested in trial NCT02236559?
The interventions under investigation include: Vapotherm (DEVICE), Noninvasive positive pressure ventilation (NIPPV) (DEVICE).
Who is sponsoring clinical trial NCT02236559?
This trial is sponsored by Vapotherm, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02236559 being conducted?
This trial has 5 study locations across Georgia, South Carolina, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Respiratory Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Simulation Trial of Telemedical Support for Paramedics
RECRUITING · NA
-
The Maximizing Extubation Outcomes Through Educational and Organizational Research (METEOR) Trial
ACTIVE NOT RECRUITING · NA
-
Treatment of Critical Illness Polyneuromyopathy
COMPLETED · NA
-
Bougie or Stylet In Patients Undergoing Intubation Emergently (BOUGIE)
COMPLETED · NA
-
Novel Arm Restraint For Critically Ill Patients To Reduce Immobility, Sedation, Agitation and Cognitive Impairment
COMPLETED · NA
-
Feasibility of Upright Bed Position in ARDS Patients
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.